Hap Trading, LLC Actinium Pharmaceuticals, Inc. Call Options Transaction History

Hap Trading, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$4.81 - $8.48 $41,366 - $72,928	-8,600 Reduced 44.56%	10,700 $8,000
Q2 2022 Aug 12, 2022	SELL	$4.71 - $7.11 $150,249 - $226,809	-31,900 Reduced 62.3%	19,300 $6,000
Q1 2022 May 12, 2022	BUY	$4.57 - $6.4 $56,211 - $78,720	12,300 Added 31.62%	51,200 $16,000
Q4 2021 Feb 14, 2022	BUY	$6.01 - $8.8 $46,878 - $68,640	7,800 Added 25.08%	38,900 $27,000
Q3 2021 Nov 10, 2021	BUY	$5.76 - $9.67 $63,936 - $107,337	11,100 Added 55.5%	31,100 $43,000
Q2 2021 Aug 11, 2021	SELL	$7.01 - $8.63 $35,751 - $44,013	-5,100 Reduced 20.32%	20,000 $10,000
Q1 2021 May 14, 2021	BUY	$7.62 - $9.79 $191,262 - $245,728	25,100 New	25,100 $27,000

7.05M

96.6K

70.5K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $45.3M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.